Growth Hormone as Biomarker in Heart Failure

Alberto M. Marra; Emanuele Bobbio; Roberta D'Assante; Andrea Salzano; Michele Arcopinto; Eduardo Bossone; Antonio Cittadini

doi:10.1016/j.hfc.2017.08.008

Growth Hormone as Biomarker in Heart Failure

Alberto M. Marra, Emanuele Bobbio, Roberta D'Assante, Andrea Salzano, Michele Arcopinto, Eduardo Bossone, Antonio Cittadini

Research output: Contribution to journal › Review article

Abstract

The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.

Original language	English
Pages (from-to)	65-74
Number of pages	10
Journal	Heart Failure Clinics
Volume	14
Issue number	1
DOIs	https://doi.org/10.1016/j.hfc.2017.08.008
Publication status	E-pub ahead of print - Nov 17 2017

Keywords

Anabolic deficiency
Biomarker
Chronic heart failure
Growth hormone
IGF-1
Outcomes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2017.08.008

Fingerprint Dive into the research topics of 'Growth Hormone as Biomarker in Heart Failure'. Together they form a unique fingerprint.

Cite this

Marra, A. M., Bobbio, E., D'Assante, R., Salzano, A., Arcopinto, M., Bossone, E., & Cittadini, A. (2017). Growth Hormone as Biomarker in Heart Failure. Heart Failure Clinics, 14(1), 65-74. https://doi.org/10.1016/j.hfc.2017.08.008

@article{2fc301754c7d43a88dab105ab4fc36af,

title = "Growth Hormone as Biomarker in Heart Failure",

abstract = "The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.",

keywords = "Anabolic deficiency, Biomarker, Chronic heart failure, Growth hormone, IGF-1, Outcomes",

author = "Marra, {Alberto M.} and Emanuele Bobbio and Roberta D'Assante and Andrea Salzano and Michele Arcopinto and Eduardo Bossone and Antonio Cittadini",

year = "2017",

month = nov,

day = "17",

doi = "10.1016/j.hfc.2017.08.008",

language = "English",

volume = "14",

pages = "65--74",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Growth Hormone as Biomarker in Heart Failure

AU - Marra, Alberto M.

AU - Bobbio, Emanuele

AU - D'Assante, Roberta

AU - Salzano, Andrea

AU - Arcopinto, Michele

AU - Bossone, Eduardo

AU - Cittadini, Antonio

PY - 2017/11/17

Y1 - 2017/11/17

N2 - The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.

AB - The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.

KW - Anabolic deficiency

KW - Biomarker

KW - Chronic heart failure

KW - Growth hormone

KW - IGF-1

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85034231494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034231494&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2017.08.008

DO - 10.1016/j.hfc.2017.08.008

M3 - Review article

AN - SCOPUS:85034231494

VL - 14

SP - 65

EP - 74

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -